An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis
Latest Information Update: 29 May 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
Most Recent Events
- 19 Nov 2024 Status changed from active, no longer recruiting to completed.
- 30 Sep 2024 Planned End Date changed from 27 Nov 2024 to 7 Nov 2024.
- 30 Sep 2024 Planned primary completion date changed from 3 Oct 2024 to 7 Nov 2024.